tiprankstipranks
Trending News
More News >
Envoy Medical (COCH)
NASDAQ:COCH
US Market
Advertisement

Envoy Medical (COCH) AI Stock Analysis

Compare
66 Followers

Top Page

COCH

Envoy Medical

(NASDAQ:COCH)

Rating:45Neutral
Price Target:
$1.50
▲(2.04% Upside)
Envoy Medical's overall stock score is primarily affected by its weak financial performance, with negative profit margins and high leverage. The positive corporate event of capital strengthening provides some relief but is not enough to offset fundamental financial challenges. Technical indicators suggest continued short-term weakness.
Positive Factors
Product Development
The Acclaim CI, a fully implanted cochlear implant that does not require any external component, has been developed by Envoy.
Regulatory Approval
The Acclaim CI received approval for its IDE application with the FDA to begin clinical testing and has already started trials with participants.
Negative Factors
Development Risks
Envoy Medical’s devices still have long development and/or commercialization roads ahead, with high risks of clinical trials or commercial failures.
Financial Performance
Revenue was approximately $0 million, compared to estimates of $0.1 million, leading to a net loss of $9.1 million or EPS of $(0.46).

Envoy Medical (COCH) vs. SPDR S&P 500 ETF (SPY)

Envoy Medical Business Overview & Revenue Model

Company DescriptionEnvoy Medical (COCH) is a medical device company specializing in developing innovative hearing solutions. The company operates within the healthcare sector, focusing on designing and manufacturing implantable hearing devices. Envoy Medical's core product is the Esteem Hearing Implant, a fully implantable active middle ear device designed to improve hearing for individuals with sensorineural hearing loss.
How the Company Makes MoneyEnvoy Medical makes money primarily through the sale of its Esteem Hearing Implant. Revenue is generated from device sales to hospitals, clinics, and healthcare providers who perform the implantation procedures. The company may also generate income from maintenance services and replacement parts for the devices. Additionally, partnerships with healthcare institutions and collaborations for research and development could contribute to the company's revenue streams.

Envoy Medical Financial Statement Overview

Summary
Envoy Medical is struggling with financial instability, marked by declining revenues, continuous losses, and high leverage. The negative equity position, coupled with poor cash flow generation, presents significant financial risks. The company needs strategic adjustments to improve profitability and financial health.
Income Statement
15
Very Negative
Envoy Medical has experienced declining revenues with a negative revenue growth rate in the TTM period. The company is operating at a loss with negative net income, resulting in a negative net profit margin. Margins such as gross profit, EBIT, and EBITDA are negative, indicating financial instability and operational challenges.
Balance Sheet
10
Very Negative
The balance sheet reveals significant financial stress, with negative stockholders' equity indicating liabilities exceed assets. The company has a negative equity ratio and faces high leverage, evidenced by a high debt-to-equity ratio. Return on equity is negative due to ongoing losses, posing risks to financial sustainability.
Cash Flow
20
Very Negative
Cash flow analysis shows negative operating and free cash flows, highlighting challenges in generating cash from operations. The operating cash flow to net income ratio is less than one, indicating inefficiency in converting income to cash flow. Free cash flow remains negative, although there is some improvement in financing activities.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue222.00K225.00K316.00K237.00K310.00K
Gross Profit-582.00K-517.00K-473.00K-261.00K-459.00K
EBITDA-19.26M-19.81M-29.79M-8.63M-6.80M
Net Income-21.27M-20.80M-29.92M-15.92M-8.68M
Balance Sheet
Total Assets9.90M11.54M7.64M2.56M2.62M
Cash, Cash Equivalents and Short-Term Investments5.29M5.48M4.22M183.00K1.12M
Total Debt901.00K19.66M562.00K34.53M23.48M
Total Liabilities39.76M30.38M9.40M58.72M47.58M
Stockholders Equity-29.86M-18.84M-1.76M-36.20M-44.96M
Cash Flow
Free Cash Flow-15.47M-18.93M-17.81M-9.02M-7.06M
Operating Cash Flow-15.38M-17.95M-17.65M-8.80M-6.94M
Investing Cash Flow-88.00K-980.00K-153.00K-218.00K-125.00K
Financing Cash Flow19.01M20.20M21.84M8.09M8.06M

Envoy Medical Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.47
Price Trends
50DMA
1.50
Negative
100DMA
1.48
Negative
200DMA
1.64
Negative
Market Momentum
MACD
-0.01
Positive
RSI
45.43
Neutral
STOCH
35.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COCH, the sentiment is Negative. The current price of 1.47 is below the 20-day moving average (MA) of 1.55, below the 50-day MA of 1.50, and below the 200-day MA of 1.64, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 35.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COCH.

Envoy Medical Risk Analysis

Envoy Medical disclosed 46 risk factors in its most recent earnings report. Envoy Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Envoy Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$29.04M-450.47%9.47%81.37%
51
Neutral
$7.39B0.36-62.86%2.37%15.48%-2.68%
51
Neutral
$39.85M-265.18%135.03%60.67%
45
Neutral
$32.50M1697.39%-26.49%-91.23%
43
Neutral
$20.92M-329.16%2115.38%-4.40%
42
Neutral
$47.49M-51.63%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
COCH
Envoy Medical
1.47
-0.93
-38.75%
EDAP
EDAP TMS
1.29
-3.51
-73.13%
NMTC
NeuroOne Medical Technologies
0.76
0.02
2.70%
VVOS
Vivos Therapeutics
4.52
2.47
120.49%
ADGM
Adagio Medical Holdings
1.34
-4.08
-75.28%

Envoy Medical Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Envoy Medical Amends Stock Purchase Warrants Agreement
Neutral
Jul 29, 2025

Envoy Medical, Inc. announced an amendment to its existing Stock Purchase Warrants with the Meteora Parties, originally issued as part of an Equity Prepaid Forward Transaction on April 17, 2023. On July 28, 2025, the amendment adjusted the exercise price of the 3,209,511 outstanding Shortfall Warrants to a volume weighted average price formula, with a minimum price of $1.50 per share, impacting the company’s stock issuance strategy.

The most recent analyst rating on (COCH) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Envoy Medical Strengthens Capital with Promissory Note
Positive
Jul 2, 2025

On June 26, 2025, Envoy Medical, Inc. drew the remaining $5 million from a promissory note with GAT Funding, LLC, an entity controlled by Glen Taylor, a board member and controlling stockholder. As part of the agreement, Envoy issued a warrant to GAT for purchasing 750,000 shares of its Class A Common Stock at $1.48 per share, valid for two years. This financial move strengthens Envoy’s capital position, potentially impacting its market operations and stakeholder interests.

The most recent analyst rating on (COCH) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Envoy Medical Elects Directors and Amends Incentive Plan
Neutral
Jun 3, 2025

At the annual meeting, Envoy Medical‘s stockholders elected two Class II directors to the Board of Directors, ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approved executive compensation on a non-binding basis, and amended the 2023 Equity Incentive Plan. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its financial oversight and executive management structure.

The most recent analyst rating on (COCH) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 03, 2025